Biotech for less than cash value Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech for less than cash value

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Eph97	4/29/2020 11:58:08 AM
	of 684

MEI Pharma (MEIP) announced on April 14 that it will receive $100 million in an upfront cash payment from Kyowa Kirin and is eligible to receive up to an additional $582.5 million based on the achievement of specified development, regulatory and commercial milestones in the development of ME-401, MEI's oral PI3K delta inhibitor for treating relapse/refractory follicular lymphoma in Phase 2 trials now. MEI has market cap of $285M with $100M cash infusion; must be tempting as a takeover candidate. I wonder why Kyowa Kirin doesn't just buy this company outright. MEI share price as of today is $2.67.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next